UniProtKB/SwissProt variant VAR

Variant information

Variant position:

278

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LB/B

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Alanine (A) at position 278 (V278A, p.Val278Ala).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from medium size and hydrophobic (V) to small size and hydrophobic (A)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

0

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

No effect on mannose-binding ability.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs741326 [ dbSNP | Ensembl ]

Sequence information

Variant position:

278

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

328

The length of the canonical sequence.

Location on the sequence:

AGMEGDWSWVDDTPFNKVQS V RFWIPGEPNNAGNNEHCGNI

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         AGMEGDWSWVDDTPFNKVQSVRFWIPGEPNNAGNNEHCGNI

Mouse                         AGSEGDWYWVDQTSFNKEQSRRFWIPGEPNNAGNNEHCANI

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 328	C-type lectin domain family 4 member K
Topological domain	65 – 328	Extracellular
Domain	202 – 320	C-type lectin
Disulfide bond	223 – 319
Mutagenesis	285 – 285	E -> A. Loss of binding to 6'-sulfo-LacNAc and invertase.
Mutagenesis	287 – 287	N -> A. Loss of binding to 6'-sulfo-LacNAc and invertase.
Helix	278 – 280

Literature citations

Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules.
Valladeau J.; Ravel O.; Dezutter-Dambuyant C.; Moore K.; Kleijmeer M.; Liu Y.; Duvert-Frances V.; Vincent C.; Schmitt D.; Davoust J.; Caux C.; Lebecque S.; Saeland S.;
Immunity 12:71-81(2000)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; FUNCTION; SUBCELLULAR LOCATION; TISSUE SPECIFICITY; VARIANT ALA-278;

Polymorphisms in human langerin affect stability and sugar binding activity.
Ward E.M.; Stambach N.S.; Drickamer K.; Taylor M.E.;
J. Biol. Chem. 281:15450-15456(2006)
Cited for: VARIANTS ALA-278; ASP-288 AND PRO-300; CHARACTERIZATION OF VARIANT BIRGD ARG-264; CHARACTERIZATION OF VARIANTS ALA-278; ASP-288 AND PRO-300;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UJ71: Variant p.Val278Ala